Hematology, Transfusion and Cell Therapy最新文献

{"title":"Imetelstat as a novel therapeutic approach for myelodysplastic syndrome","authors":"Ammara Waheed Arain, Anushka Andani, Aayat Kashif, Radeyah Waseem","doi":"10.1016/j.htct.2024.09.2484","DOIUrl":"10.1016/j.htct.2024.09.2484","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103724"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transmitted blood infections and emerging vector-borne diseases in blood donors in northern Portugal","authors":"Ana Mota ,&nbsp;Margarida Fonseca Cardoso","doi":"10.1016/j.htct.2025.103734","DOIUrl":"10.1016/j.htct.2025.103734","url":null,"abstract":"<div><h3>Background</h3><div>Screening of transfusion-transmissible infectious agents of blood components is carried out in order to guarantee the safety of the transfusion process. The objective of this investigation was to characterize cases positive for transfusion-transmissible infectious agents in blood donations in the North of Portugal.</div></div><div><h3>Method</h3><div>Data from 2010 to 2022 of the Local Health Unit-Santo Antonio were used for this study. In specific epidemiological situations, malaria, Chagas disease and West Nile virus were screened.</div></div><div><h3>Main results</h3><div>Over 12 years, the health unit, received 137,751 donations with 108 positive tests. The proportions of human immunodeficiency viruses, syphilis, human hepatitis viruses type B and C varied between 0 and 44/100,000 donations. In this period, two cases of malaria were detected in 2020–2021, and 21 were detected in 2022 corresponding to 52.1/1000 donations screened. In 2022, two cases of Chagas disease and no cases of West Nile virus were detected.</div></div><div><h3>Conclusion</h3><div>These results highlight the importance of a rigorous investigation at the time of donation in which the donor's history, including origin and movement in areas of greater geographic risk, are assessed. The recent and increasing detection of cases of malaria and Chagas disease confirms the presence of emerging infectious diseases transmitted by vectors, including mosquitoes, in blood donors. The increased risk of vector-borne diseases in Europe is a public health problem and represents a new challenge in screening donations.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103734"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143351157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy","authors":"Frank Nunes ,&nbsp;Breno Moreno de Gusmão ,&nbsp;Franciely Bueno Wiginesk ,&nbsp;Euler Manenti ,&nbsp;Juliana Soares ,&nbsp;Mizianne Garcia Freitas ,&nbsp;Juliane Dantas Seabra-Garcez ,&nbsp;Alexandre Manoel Varela ,&nbsp;João Pedro Passos Dutra ,&nbsp;Bruno Cesar Bacchiega ,&nbsp;Tânia Félix Lorenzato da Fonseca Peixoto ,&nbsp;Carolina Maria Pinto Domingues de Carvalho e Silva ,&nbsp;Renato D. Lopes ,&nbsp;Ariane Vieira Scarlatelli Macedo","doi":"10.1016/j.htct.2024.06.008","DOIUrl":"10.1016/j.htct.2024.06.008","url":null,"abstract":"<div><div>Chimeric antigen receptor T-cell therapy represents an innovative approach to immunotherapy and currently stands out, particularly for oncohematological patients refractory to traditional treatments. Ongoing trials are further expanding its clinical use for new oncological and non-oncological indications, potentially leading to newer treatment options soon.</div><div>This new approach, however, also presents challenges, including cardiovascular toxicity. Little is reported in pivotal studies, and some recent retrospective observations suggest a non-negligible incidence of side effects with presentation ranging from mild adverse cardiovascular events to fatal complications in which, in most cases, there is a direct or indirect association with cytokine release syndrome.</div><div>In this literature review, the hypotheses of an important interface between cytokine release syndrome and cardiotoxicity by chimeric antigen receptor T-cell therapy will be addressed, as will current knowledge about risk factors for cardiotoxicity and recommendations for pre-therapy evaluation, post-infusion monitoring and clinical management of these complications.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103693"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital thrombotic thrombocytopenic purpura and human leukocyte antigen analysis–an amazing clue","authors":"Cevat İlteriş Kıkılı,&nbsp;Demet Kıvanç,&nbsp;Hayriye Şentürk Çiftçi,&nbsp;Mustafa M. Özbalak,&nbsp;Mustafa N. Yenerel,&nbsp;Meliha Nalçacı,&nbsp;Fatma S. Oğuz,&nbsp;Sevgi K. Beşışık","doi":"10.1016/j.htct.2025.103746","DOIUrl":"10.1016/j.htct.2025.103746","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103746"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization","authors":"Mehmet Bakırtaş ,&nbsp;Bahar Uncu Ulu ,&nbsp;Tuğçe Nur Yiğenoğlu ,&nbsp;Semih Başcı ,&nbsp;Ali Kılınç ,&nbsp;Tahir Darçın ,&nbsp;Fatma Nurbüke Şarkışla ,&nbsp;Derya Şahin ,&nbsp;Nuran Ahu Baysal ,&nbsp;Dicle İskender ,&nbsp;Merih Kızıl Çakar ,&nbsp;Mehmet Sinan Dal ,&nbsp;Fevzi Altuntaş","doi":"10.1016/j.htct.2025.103738","DOIUrl":"10.1016/j.htct.2025.103738","url":null,"abstract":"<div><h3>Introduction</h3><div>Granulocyte colony-stimulating factor (G-CSF) is the most prevalently used growth factor for peripheral blood hematopoietic stem cell (HSC) mobilization. Most centers split the granulocyte colony-stimulating factor in two daily doses, whereas some centers administer one dose per day. This study aims to investigate the effect of the filgrastim dosing schedule on the quantity of hematopoietic stem cells collected after mobilization in healthy donors.</div></div><div><h3>Methods</h3><div>A total of 251 healthy donors mobilized in our center were included in the study. Mobilization was either once a day (filgrastim 1 × 10 mg/kg/day) or twice a day (filgrastim 2 × 5 mg/kg/day).</div></div><div><h3>Results</h3><div>White blood cell and peripheral CD34⁺ cell numbers were significantly higher in the Twice-a-day Group on the fifth day compared to the Once-a-day Group. No statistically significant difference was shown between the two groups regarding the number of CD34⁺ cells collected on the first apheresis day or the number of apheresis procedures needed to achieve the targeted number of CD34⁺ cells.</div></div><div><h3>Conclusion</h3><div>This study revealed that one daily dose of 10 mg/kg filgrastim is as effective as administering the same dose split on two days for an adequate amount of CD34⁺ cells in healthy donors.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103738"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the contribution of myelofibrosis to a leukoerythroblastic blood picture","authors":"Stephen E. Langabeer","doi":"10.1016/j.htct.2025.103735","DOIUrl":"10.1016/j.htct.2025.103735","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103735"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil","authors":"Larissa Hilario Dulley ,&nbsp;Arthur Gomes Oliveira Braga ,&nbsp;Guilherme Garcia Rodrigues ,&nbsp;Sergio Costa Fortier ,&nbsp;Carlos Sérgio Chiattone ,&nbsp;Talita Maira Bueno da Silveira","doi":"10.1016/j.htct.2024.06.003","DOIUrl":"10.1016/j.htct.2024.06.003","url":null,"abstract":"<div><div>The German Hodgkin Study Group developed the escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) protocol as a treatment strategy for advanced-stage Hodgkin's lymphoma. In Brazil, as well as in other countries, procarbazine has been replaced with dacarbazine due to the limited availability of procarbazine. The Hematology Center at Irmandade da Santa Casa de Misericórdia in São Paulo adopted and modified the escalated BEACOPP protocol, substituting prednisone with dexamethasone and incorporating two different doses of dacarbazine: 375 mg/m²/day on Day 8 or the original dose of 250 mg/m²/day on Days 2 and 3. This adjustment was made in response to the anticipated toxicity profile. This study aimed to compare the two different doses in the protocols (375 mg/m²/cycle versus 500 mg/m²/cycle) administered to patients with advanced Hodgkin's lymphoma in similar periods. This retrospective study analyzed the data of 31 patients at a single center in Brazil from 2019 to 2021. Seventeen of the 31 patients received 500 mg/m²/cycle (500 Group), while 14 received 375 mg/m²/cycle (375 Group). At the end of the protocol, 71% of the patients in the 375 Group and 76% in the 500 Group achieved complete remission. On analyzing the number of cycles that patients presented with febrile neutropenia, the 500 Group had three times more events (17.9%) than the 375 Group (6.09% - p-value = 0.04). In the 500 Group, 47.1% needed to change the protocol to ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine) due to toxicity. In this limited cohort from a single public center in Brazil, the use of 375 mg/m² of dacarbazine per cycle of the modified escalated BEACOPP protocol emerged as a safer strategy, maintaining treatment efficacy without compromising response in patients with advanced Hodgkin's lymphoma.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103682"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An approach to autologous stem cell mobilization: trying to define good mobilizers","authors":"Sara Montolio Chiva,&nbsp;Paula Gomez Fernandez,&nbsp;Antonio Manuel Gutiérrez Garcia,&nbsp;Maria del Carmen Ballester Ruiz,&nbsp;Antonia Sampol Mayol,&nbsp;Albert Perez Montaña","doi":"10.1016/j.htct.2024.04.126","DOIUrl":"10.1016/j.htct.2024.04.126","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Stem cell mobilization is a well-known procedure to harvest hematopoietic stem cells for autologous stem cell transplantation in certain hematologic diseases. Numerous studies have been conducted to identify risk factors for poor mobilization but there are no studies that identify good mobilizers. In our hospital, we decided to explore good mobilizers, defining them as those with ≥40 CD34⁺ cells/μL on Day +4 in order to start early apheresis.</div></div><div><h3>Material and methods</h3><div>A descriptive retrospective study was performed at Hospital Universitari Son Espases. A total of 198 patients mobilized with doses of around 10 µg/kg of granulocyte colony-stimulating factor (G-CSF) every 12 h were analyzed for autologous collection between January 2015 and September 2022. Fifty patients who had ≥40 CD34⁺ cells/μL on Day +4 started early apheresis; the rest continued mobilization as planned. Success was defined as obtaining over 2.5 × 10⁶ CD34⁺ cells/kg in a single apheresis.</div></div><div><h3>Results</h3><div>The necessary number of CD34⁺ cells/kg to perform an autologous stem cell transplantation was reached in a single apheresis session in 62 % of patients with ≥40 CD34⁺ cells/μL in peripheral blood. A cutoff of 102 CD34⁺ cells/μL on Day +4 was shown to have the best success rate (94 %)<strong>.</strong> In an analysis of success, age, previously failed mobilization and having one or more adverse factors for bad mobilization were statistically significant.</div></div><div><h3>Conclusion</h3><div>Patients considered as good mobilizers were matched with our factors of poor mobilization, revealing that most patients (79 %) had none or only one risk factor for poor mobilization. Apheresis on Day +4 in good mobilizers was shown to be an effective alternative to reduce mobilization duration and decrease the amount of granulocyte-colony stimulating factor administered.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103688"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of blueberry extract on hematological response in phenylhydrazine-induced hemolytic anemia","authors":"Daniela Drosdowski,&nbsp;Patrick Türck,&nbsp;Silvio Tasca,&nbsp;Gabriel de Lima Rosa,&nbsp;Edson Fernando Muller Guzzo,&nbsp;Sara Elis Bianchi,&nbsp;Adriana Simon Coitinho,&nbsp;Cristina Campos Carraro,&nbsp;Adriane Belló-Klein,&nbsp;Alexandre Luz de Castro,&nbsp;Valquiria Linck Bassani,&nbsp;Alex Sander da Rosa Araujo","doi":"10.1016/j.htct.2025.103744","DOIUrl":"10.1016/j.htct.2025.103744","url":null,"abstract":"<div><div>The objective of this study was to explore the therapeutic effect of blueberries on hematological parameters, oxidative stress, and interleukin-10 levels in acute hemolytic anemia induced by the administration of an intraperitoneal injection of 40 mg/kg phenylhydrazine. Male Wistar rats were divided into three groups: Control, anemia (PHZ), and anemia plus blueberries (PHZ+BB). Blueberries were administered via oral gavage (250 mg/day). The erythrocyte osmotic fragility, splenomegaly, iron metabolism, hematological analysis, reactive oxygens species, sulfhydryl group, and interleukin-10 levels were evaluated. The erythrocyte osmotic fragility (in 0.85% and 0.55% sodium chloride solution) and spleen weight-to-body weight ratio (∼400%) were elevated in the PHZ and PHZ+BB Groups compared to the controls (<em>p</em>-value &lt; 0.05). Increased transferrin and reactive oxygens species levels were found in the PHZ (15%) compared to the Control Group (<em>p</em>-value &lt; 0.05). There was an immune inflammatory response in the PHZ Group due to increases in the total leukocyte (300%), lymphocyte (100%), and neutrophil (400%) counts compared to the Control Group (<em>p</em>-value &lt; 0.05); the PHZ Group showed increased interleukin-10 levels (100%) compared to the Control Group (<em>p</em>-value &lt; 0.05). Blueberries showed a partial protective effect on these parameters, since there were lower neutrophil and lymphocyte counts and diminished interleukin-10 levels in the PHZ+BB Group compared to the PHZ Group (<em>p</em>-value &lt; 0.05). In addition, blueberries increased sulfhydryl group levels (<em>p</em>-value &lt; 0.05). These data suggest a protective role of blueberries against inflammatory response and oxidative stress in an acute hemolytic anemia model.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103744"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare case of discrepant ABO typing between mother and newborn caused by para-Bombay AB phenotype","authors":"Tatiane Aparecida de Paula Vendrame ,&nbsp;Giovana Faria Devides ,&nbsp;Nayara Morais Silva ,&nbsp;Marcela Custódio Mendes ,&nbsp;Márcia Léia Morais Sampaio ,&nbsp;Marcia Miyuki Nakamura ,&nbsp;Greice Ap.Chetta de Klerk ,&nbsp;Lilian Castilho ,&nbsp;Afonso Cortez ,&nbsp;Flavia Roche Moreira Latini ,&nbsp;Carine Prisco Arnoni","doi":"10.1016/j.htct.2025.103742","DOIUrl":"10.1016/j.htct.2025.103742","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103742"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}